Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.